Join the Hemolytic Uremic Syndrome group to help and get support from people like you.
Hemolytic Uremic Syndrome News
Child Dies After Suspected E. Coli Outbreak Linked To Butcher Shops in France
TUESDAY, June 24, 2025 — A 12-year-old girl has died and seven other children were sickened after a suspected outbreak of a rare foodborne illness in northern France. Before getting sick, French o...
FDA Approves Epysqli (eculizumab-aagh), a Biosimilar to Soliris
INCHEON, South Korea, July 22, 2024 (GLOBE NEWSWIRE) – Samsung Bioepis Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA)...
FDA Approves Bkemv (eculizumab-aeeb), an Interchangeable Biosimilar to Soliris
May 28, 2024 – Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is...
Alexion Receives FDA Approval for Ultomiris (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (AHUS)
BOSTON October 18, 2019 --(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved Ultomiris (ravulizumab-cwvz) for the...
FDA Medwatch Alert: Soliris (eculizumab) Concentrated Solution for IV Infusion by Alexion: Recall - Visible Particulates
ISSUE: Alexion Pharmaceuticals, Inc. announced that it is initiating a voluntary recall of certain lots of Soliris (eculizumab) 300mg/30 mL concentrated solution for intravenous infusion. The...
Soliris (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
CHESHIRE, Conn.--(BUSINESS WIRE)--Sep 23, 2011 - Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Soliris® (eculizumab) for the treatment of ...